Rab25 induces chemoresistance towards cisplatin, a first-line chemotherapeutic agent, commonly used in the treatment of patients with various types of cancer, such as advanced non-small cell lung cancer patients [62, 63], metastatic breast cancer [64] and ovarian cancer [65]. Here, RAB25 is linked to non-small cell lung carcinoma.